Browsing Tag
Multiple myeloma
50 posts
Darzalex Faspro moves closer to FDA approval as first therapy for high-risk smoldering multiple myeloma
Find out how Darzalex Faspro could become the first FDA-approved therapy for high-risk smoldering multiple myeloma, reshaping early myeloma care.
Caribou Biosciences set for key webcast showcasing CRISPR-engineered CAR-T breakthroughs in blood cancers
Discover how Caribou Biosciences is preparing to reveal breakthrough CRISPR-edited allogeneic CAR-T data in lymphoma and myeloma during its investor webcast.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Can immune-based doublets push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can immune-based doublets like TECVAYLI and DARZALEX FASPRO push CAR-T and bispecifics into earlier multiple myeloma treatment lines?
Can Johnson & Johnson’s TECVAYLI and DARZALEX FASPRO regimen redefine first-line multiple myeloma treatment?
Johnson & Johnson’s TECVAYLI + DARZALEX FASPRO combo hit 100% MRD negativity in new myeloma trial. Can this immune-based regimen redefine frontline care?
Exicure completes Phase 2 trial of GPC-100 for stem cell mobilization in multiple myeloma patients
Exicure (NASDAQ: XCUR) completes final patient visit in Phase 2 GPC-100 trial for stem cell mobilization in multiple myeloma; topline results expected Q4 2025.
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Caribou Biosciences launches CB-010 GALLOP Phase 1 trial in lupus
Caribou Biosciences, Inc., a clinical-stage leader in CRISPR genome-editing biopharmaceuticals, has announced the initiation of its CB-010 GALLOP…
Ichnos Glenmark presents data from Phase 1 study of ISB 2001 in multiple myeloma
In a presentation at the 66th American Society of Hematology Annual Meeting, Ichnos Glenmark Innovation (IGI) unveiled promising…